Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study
Authors:
Open Access
- 17 April 2021
- journal article
- research article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 14 (1) , 1-12
Abstract
Background: The onset of the COVID-19 pandemic forced the Dutch national screening program to a halt and increased the burden on health care services, necessitating the introduction of specific breast cancer treatment recommendations from week 12 of 2020. We aimed to investigate the impact of COVID-19 on the diagnosis, stage and initial treatment of breast cancer. Methods: Women included in the Netherlands Cancer Registry and diagnosed during four periods in weeks 2–17 of 2020 were compared with reference data from 2018/2019 (averaged). Weekly incidence was calculated by age group and tumor stage. The number of women receiving initial treatment within 3 months of diagnosis was calculated by period, initial treatment, age, and stage. Initial treatment, stratified by tumor behavior (ductal carcinoma in situ [DCIS] or invasive), was analyzed by logistic regression and adjusted for age, socioeconomic status, stage, subtype, and region. Factors influencing time to treatment were analyzed by Cox regression. Results: Incidence declined across all age groups and tumor stages (except stage IV) from 2018/2019 to 2020, particularly for DCIS and stage I disease (p < 0.05). DCIS was less likely to be treated within 3 months (odds ratio [OR]wks2–8: 2.04, ORwks9–11: 2.18). Invasive tumors were less likely to be treated initially by mastectomy with immediate reconstruction (ORwks12–13: 0.52) or by breast conserving surgery (ORwks14–17: 0.75). Chemotherapy was less likely for tumors diagnosed in the beginning of the study period (ORwks9–11: 0.59, ORwks12–13: 0.66), but more likely for those diagnosed at the end (ORwks14–17: 1.31). Primary hormonal treatment was more common (ORwks2–8: 1.23, ORwks9–11: 1.92, ORwks12–13: 3.01). Only women diagnosed in weeks 2–8 of 2020 experienced treatment delays. Conclusion: The incidence of breast cancer fell in early 2020, and treatment approaches adapted rapidly. Clarification is needed on how this has affected stage migration and outcomes.Keywords
Funding Information
- ZonMw (10430022010014)
This publication has 11 references indexed in Scilit:
- Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensusAnnals of Oncology, 2020
- Breast-contour preserving procedures for early-stage breast cancer: a population-based study of the trends, variation in practice and predictive characteristics in Denmark and the NetherlandsBreast Cancer Research and Treatment, 2020
- Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemicnpj Breast Cancer, 2020
- ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast CancerESMO Open, 2020
- Fewer cancer diagnoses during the COVID-19 epidemic in the NetherlandsThe Lancet Oncology, 2020
- LncRNA RP11-19E11 is an E2F1 target required for proliferation and survival of basal breast cancernpj Breast Cancer, 2020
- Preoperative Delays in the Treatment of DCIS and the Associated Incidence of Invasive Breast CancerAnnals of Surgical Oncology, 2019
- Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer AuditEuropean Journal of Surgical Oncology, 2019
- A prediction model for underestimation of invasive breast cancer after a biopsy diagnosis of ductal carcinoma in situ: based on 2892 biopsies and 589 invasive cancersBritish Journal of Cancer, 2018
- Timing of Breast Cancer Surgery-How Much Does It Matter?The Breast Journal, 2017